Millrace Asset Group’s Myriad Genetics MYGN Stock Holding History

Millrace Asset Group’s Portfolio MYGN Stock Details MYGN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q3	–	Sell	-29,222	Closed	-$812K	–	72
2019 Q2	$812K	Sell	29,222 -29,080	-50%	-$821K	0.84%	60
2019 Q1	$1.94M	Buy	58,302 +5,511	+10%	+$168K	1.63%	29
2018 Q4	$1.53M	Buy	52,791 +13,819	+35%	+$497K	1.41%	40
2018 Q3	$1.79M	Sell	38,972 -17,500	-31%	-$778K	1.4%	38
2018 Q2	$2.11M	Buy	56,472 +33,700	+148%	+$1.14M	1.61%	29
2018 Q1	$673K	Sell	22,772 -9,066	-28%	-$307K	0.65%	57
2017 Q4	$1.09M	Sell	31,838 -900	-3%	-$30.4K	1.05%	48
2017 Q3	$1.18M	Sell	32,738 -45,103	-58%	-$1.29M	1.11%	47
2017 Q2	$2.01M	Buy	+77,841	New	+$1.65M	1.9%	17
2015 Q2	–	Sell	-30,964	Closed	-$1.1M	–	59
2015 Q1	$1.1M	Buy	+30,964	New	+$1.11M	1.21%	43

Other funds holding MYGN

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

GCM

Glenview Capital Management New York $3.98B AUM 20.52% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

EARNEST Partners Atlanta, Georgia $24.3B AUM 34.41% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

DGI

Disciplined Growth Investors Minneapolis, Minnesota $4.89B AUM 33.85% 1-Year Est. Return

D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Millrace Asset Group's MYGN Position: Q3 2019 in Review

Millrace Asset Group sold out of Myriad Genetics (MYGN) in Q3 2019, closing a stake of 29,222 shares — an estimated $812K sold.

Millrace Asset Group first reported a position in MYGN in Q1 2015 and held it in 10 quarters. The position peaked at $2.11M in Q2 2018. 221 funds tracked by Wall St. Rank hold MYGN as of Q3 2019.

Millrace Asset Group reported no remaining Myriad Genetics position as of Q3 2019 after selling out during the quarter.
Millrace Asset Group sold 29,222 Myriad Genetics shares in Q3 2019, an estimated $812K.
Millrace Asset Group first reported a position in Myriad Genetics in Q1 2015 and held it in 10 quarters.
Millrace Asset Group's Myriad Genetics position peaked at $2.11M in Q2 2018.
221 funds tracked by Wall St. Rank held Myriad Genetics as of Q3 2019.

Based on Millrace Asset Group's 13F filing for Q3 2019, filed 14 Nov 2019.